Company Filing History:
Years Active: 2022-2025
Title: Innovations by Inventor Shelley Izquierdo in Antibody Development
Introduction
Shelley Izquierdo, based in Berkeley, CA, is a notable inventor with a keen focus on innovative developments in the field of biotechnology. With a total of three patents to her name, she has made significant contributions, particularly in the creation of antibodies targeting signal-regulatory protein alpha. These advancements have the potential to enhance therapeutic methods used in various medical applications.
Latest Patents
Izquierdo's latest patents revolve around the production of isolated antibodies that bind to distinct extracellular domains of human SIRP-α polypeptides. Specifically, her patents emphasize both SIRP-α v1 and v2 polypeptides. The antibodies developed can also interact with corresponding polypeptides from monkeys, mice, and even human SIRP-β and SIRP-γ polypeptides. In these innovative embodiments, her antibodies are designed to either block binding interactions between human SIRP-α and CD47 or decrease the affinity of this binding, thereby opening new avenues for therapeutic mechanisms. Additionally, the patents include methods, polynucleotides, vectors, and host cells that further support clinical applications.
Career Highlights
Shelley Izquierdo is associated with Alx Oncology Inc., a company focused on leveraging advanced biological treatments in oncology. Her dedication to innovation in antibody development showcases her expertise and commitment to advancing medical science. Throughout her career, her research has underscored the importance of targeted therapies in improving patient outcomes.
Collaborations
In her professional journey, Izquierdo collaborates with notable colleagues such as Hong Wan and Steven Elliot Kauder. This teamwork further enhances the innovative spirit at Alx Oncology Inc. and fosters an environment where groundbreaking discoveries can flourish.
Conclusion
Shelley Izquierdo stands out as a pioneering inventor in the field of biotechnology, demonstrating how innovative antibodies can significantly influence therapeutic strategies. Her research and patents are not only a testament to her skills but also a valuable asset to the ongoing fight against diseases, particularly within oncology. With her continued contributions, the future of antibody therapies looks promising.